glp 1 nejm publishes Phase 3 trial results for orforglipron, an oral GLP-1 obesity medication. | Scott Isaacs, MD, FACP, FACE posted on the topic New @NEJM review on GLP-1

Provider practice habits and barriers to care in obesity management in a large multicenter health system

Carnitine-deprived piglets had evidence of lipid deposition in liver and skeletal muscle and tended to have a higher incidence of muscle weakness and cardiac failure

15 Alzheimers Disease GLP1 receptor agonists are under investigation for their potential impact on neurodegenerative diseases, such as Alzheimers disease

However, some lawsuits claim that Ozempic has caused people to suffer painful, disabling, and life-threatening gastrointestinal issues

The compounding pharmacy workaround to address a medication shortage is helpful, as long as its done properly